TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants (born before 37+0 gestation weeks) who are diagnosed to have a hemodynamically significant PDA and who, according to the decision of the attending clinician, need ibuprofen therapy, are eligible to this trial.~Exclusion Criteria:~* severe malformation or suspected chromosomal defect~* other very severe life-threatening disease (e.g. very severe birth asphyxia or persistent pulmonary hypertension, etc.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Pedea 5mg/mL and Paracetamol 10mg/mL (Type: EXPERIMENTAL): Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
- Pedea 5mg/mL and 0.45 sodium chloride (Type: PLACEBO_COMPARATOR): IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
- Indomethacin 25mg/mL and Paracetamol10mg/mL (Type: EXPERIMENTAL): Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
- Indomethacin 25mg/mL and 0.45 sodium chloride (Type: PLACEBO_COMPARATOR): Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women ≥ 18 years of age~* Covid-19 Positive~* Hospitalized patients able to provide informed consent~* Cardiac injury (as evidenced by any of the following)~  1. Elevated troponin level~ 2. Elevated BNP level~ 3. New ischemic or arrhythmogenic ECG/telemetry changes~ 4. New decrease in Left Ventricular Ejection Fraction (LVEF) or new pericardial effusion on echocardiogram~Exclusion Criteria:~* Pregnancy, breastfeeding mothers, and women of childbearing age who are unable to use adequate contraception, which includes:~  1. Intrauterine devices (IUD), contraceptive implants, or tubal sterilization~ 2. Hormone method with a barrier method~ 3. Two barrier methods~ 4. If a partner's vasectomy is the chosen method of contraception, a hormone or barrier method must also be used in conjunction~* History of severe hematologic or neuromuscular disorder~* Co-administration of Cytochrome P450 3A4 (CYPA3A4) and P-glycoprotein transport inhibitor~* Severe renal impairment with concomitant hepatic impairment~* Concurrent use of colchicine and strong or P-glycoprotein inhibitor with renal or hepatic impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Hospitalized covid-19 patients treated with colchicine plus current care per institution treating physicians.
- Control (Type: NO_INTERVENTION): Hospitalized covid-19 patients treated with current standard of care (per institution treating physicians) alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: VAC Bioburden Wound Care Assessment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18+yo with an injury or infection of the upper or lower extremity for which surgical debridement (in the operating room) followed by VAC application is planned.~Exclusion Criteria:~- Patient with wounds distal to the ankle.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wound vac application (Type: ACTIVE_COMPARATOR): Wound vac application for open upper/lower extremity open wound
- Wound vac application including irrigation (Type: ACTIVE_COMPARATOR): Wound vac application WITH irrigation for upper/lower extremity open wound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed COVID-19 infection~2. Age =/\>40 or diabetes or known coronary disease or hypertension~3. Requires hospital admission for further clinical management.~Exclusion Criteria:~1. Clear evidence of an acute coronary syndrome or myo-pericarditis that requires specific treatment that precludes randomization.~2. Evidence of active bleeding~3. Pregnancy.~4. Age \<18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Active Arm (Type: EXPERIMENTAL): None
- Control Arm (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients that are scheduled for vitrectomy surgery, regardless of the indication~* Both vitrectomy-only and combined phaco-vitrectomy surgeries~* Primary or repeat vitrectomy~* General or local anesthesia, or combination~* All ages~* Informed consent (from parents in patients \<18 years old)~Exclusion Criteria:~* Unable to obtain informed consent from patient (or from parents in children)~* No post-operative 8 week visit is anticipated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IRIS vitrectomy device (Type: EXPERIMENTAL): all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cook Iliac Branch Graft Post-market Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CE-Marked Cook Iliac Branch Graft (e.g., Zenith® Branch Endovascular Graft-Iliac Bifurcation, Zenith® Helical Branch Endovascular Graft)~* Registry data are de-identified with respect to patient.~Exclusion Criteria:~* Patient for whom this device would not normally be considered standard of care.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cook Iliac Branch Graft (Type: None): Patients implanted with a Cook Iliac Branch Graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo elective abdominal surgery~* At least 18 years of age~* Able to understand and willing to sign an IRB-approved informed consent document~Exclusion Criteria:~* Doesn't have access to smartphone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phone Call (Type: EXPERIMENTAL): * Patients will be provided with a Fitbit wristband \& assistance to set up on smart phone~* Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery~* The group will receive a phone call 7 days into their preoperative period to identify barriers, provide available resources, \& encourage continuation of prehabilitation activities~* The physician extender will talk with the patient to identify barriers to prehabilitation activities that the patient may have experienced during the first 7 days of activity tracking \& provide recommendations \& resources to overcome those barriers when possible. The physician extender will encourage the patient to continue prehabilitation activities until the day of operation to meet goals. Following surgery, we will analyze Fitbit data to determine if the intervention had an impact on the patient's prehabilitation activity with the non-intervened patient group used as a control
- No Phone Call (Type: NO_INTERVENTION): * Eligible patients will be provided with a Fitbit wristband \& assistance to set up on smart phone~* Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ataluren (PTC124) in Cystic Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to provide written informed consent (parental/guardian consent and participant assent if less than \[\<\] 18 years of age).~* Evidence of completed participation in the double-blind study, PTC124-GD-009-CF (Study 009).~* Body weight greater than or equal to (≥) 16 kilograms (kg).~* Performance of a valid, reproducible spirometry test using the study-specific spirometer during the screening period.~* Confirmed laboratory values within the central laboratory ranges at screening.~* In male and female participants who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and 60-day follow-up period.~* Willingness and ability to comply with all study procedures and assessments, including scheduled visits, drug administration plan, laboratory tests, and study restrictions.~Key Exclusion Criteria:~* Chronic use of systemic tobramycin within 4 weeks prior to screening.~* Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to screening or between screening and randomization.~* Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks prior to screening and randomization.~* Known hypersensitivity to any of the ingredients or excipients of the study drug.~* Exposure to another investigational drug within 4 weeks prior to screening.~* Treatment with intravenous antibiotics within 3 weeks prior to screening.~* History of solid organ or hematological transplantation.~* Ongoing immunosuppressive therapy (other than corticosteroids).~* Positive hepatitis B surface antigen, hepatitis C antibody test or human immunodeficiency virus (HIV) test.~* Known portal hypertension.~* Pregnancy or breast-feeding.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ataluren (Type: EXPERIMENTAL): Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Computational Simulation of Patellar Instability

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of recurrent patellar dislocation~* Plan to be surgically treated at Akron Children's Hospital~Exclusion Criteria:~* Additional Injuries unrelated to patellar instability for the knee of interest~* Implantation of metallic hardware that could cause artifacts within MRI scans~* Inability to remain still during MRI scans

- Gender: ALL
- Minimum Age: None
- Maximum Age: 89 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypnopuncture for In Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females patients age 18 years and older~* Primary infertility with negative endocrinology and US findings on evaluation~* Following two failed cycles of either IVF or ICSI, defined as no clinical pregnancy (presence of fetal sac on ultrasound examination 6 weeks after embryo transfer).~* No underlying Axis 1 psychiatric disorder~* Ability to comply with study protocol~Exclusion Criteria:~* Patients displaying symptoms of overt Axis-1 psychopathology such as schizophrenia or severe depression.~* Current use of any CAM therapy~* Current use of any fertility treatment other than those prescribed by the fertility clinic.~* Inability to comply with the study protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Hypnopuncture Treatment
- 2 (Type: NO_INTERVENTION): Conventional IVF/ICSI treatment only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adult patients over 18 years old with diabetes (both sexes) presenting without any kidney disease or with ESRD on hemodialysis~* Undergoing major elective surgery procedures such as abdominal, pulmonary, GU/GYN, vascular, renal, neurologic, and orthopedic surgery~* Signed informed consent for the study.~* Patients with elevated preoperative blood glucose of a value \> 150 mg/dL or \< 350 mg/dL~* English-speaking~* Baseline chemistry with a potassium at or above 3.5~Exclusion criteria:~* Patients under the age of 18.~* Pregnant women. (Pregnant women have altered glucose metabolism; specific insulin regimen used for pregnant women)~* Patient does not give informed consent for the study.~* Patient does not have decisional capacity or a surrogate.~* Patient cannot understand or read English.~* Patients with a preoperative blood glucose \< 150 mg/dL or \>350 mg/dL~* Patients without diabetes~* Patients with kidney disease that are not on hemodialysis~* A history of frequent hypoglycemia in the month prior to surgery by history or a change in insulin dose for hypoglycemia in the month prior to surgery~* Patients taking steroids or patients that will receive steroids during their surgery~* Any patients who refuse to remain NPO except water in the two hour window after their last insulin dose~* Patients scheduled for cardiac, thoracic and emergency surgeries~* Patients who have taken or received insulin or oral hypoglycemic agents after 12 am on the day of surgery.~* Patients have not adhered to the NPO status.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Patients with diabetes and ESRD (Type: OTHER): Patients with diabetes and end stage renal disease (ESRD)
- Patients with diabetes and no ESRD (Type: OTHER): Patients with diabetes and no end stage renal disease (ESRD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: STEPS Trial - Spheramine Safety and Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Parkinson's disease for at least 5 years~* Good response to L-dopa~* Age 30 to 70 years~* Optimum oral therapy~Exclusion Criteria:~* Tremor only~* Dementia~* Very severe dyskinesia~* Previous brain surgery including deep brain stimulation~* Malignant disease

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum age: 12 years~* Good general health confirmed by clinical history and a physical and skin examination (excluding area of skin with impetiginous eczema).~* Diagnosis of impetiginous eczema.~* Ability to understand the procedures of the protocol and follow the requirements during the course of the study.~* Results of routine laboratory tests - hemogram with leukogram and platelet count, creatinine, glucose, sed. rate, IgE level and transaminases; along with plasma cortisol and adrenocorticotropic hormone (ACTH) levels prior to the start of the treatment. These results must all be within normal limits or not clinically relevant in order to be included in the trial.~Exclusion Criteria:~* Pregnant participants or women of childbearing age who are not using birth control methods considered reliable by the attending physician.~* Participants with a history of hypersensitivity to any of the components of the medication being studied.~* Participants in whom the extent or severity of the lesions requires treatment of a different type than what is planned for this trial.~* Participants who need any other type of topical or systemic medication during the trial that might affect the course of the disease.~* Participants who have been treated with other topical medications during the 14-day period prior to the start of the trial.~* Participants who have received systemic corticosteroids or any other immunosuppressant medication during the 28-day period prior to the start of the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QUADRIDERME® cream (Type: EXPERIMENTAL): QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
- Betamethasone and Gentamicin (Type: ACTIVE_COMPARATOR): Combination of betamethasone diproprionate cream and gentamicin sulfate cream
- Betamethasone (Type: ACTIVE_COMPARATOR): Betamethasone diproprionate cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Study participants must meet all of the following inclusion criteria to participate in the study:~* Adult female study participants (≥18 years) with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel~* Study participants must be capable and willing to provide informed consent, and be willing and able to complete the study questionnaires during the study~Exclusion Criteria:~Study participants who fulfill any of the following criteria will be excluded:~* Patients with metastatic breast cancer~* History of other cancers (except squamous and basal cell carcinoma)~* Autoimmune disorders~* Presence of major active infection for which antibiotics and/or antivirals are prescribed within the last 14 days (chronic or acute, eg, sepsis, HIV, pneumonia, active COVID infection)~* Pregnant women~* Participation in an additional study at the time of enrollment where the intervention could potentially alter CIPN risk (unless in the control arm)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study group (Type: None): Adult females with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy